Clinical Medical Research Sp. z o.o.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
Clinical trials at Clinical Medical Research Sp. z o.o. focus on conditions such as heart failure, hypertension, and atherosclerotic disease, aiming to test new therapies that reduce cardiovascular events and improve patient outcomes.
- Evaluation of novel agents for reducing heart failure hospitalizations
- Strategies to lower blood pressure in high‑risk populations
- Prevention of major adverse cardiovascular events in patients with established disease
The site’s cardiovascular program integrates cutting‑edge research to address the growing burden of heart disease in Europe.
Eye Diseases
Studies target diabetic macular edema and other vision‑impairing conditions, evaluating treatments that aim to preserve or restore sight.
- Assessment of intravitreal therapies for macular edema
- Dose‑response investigations for retinal disease agents
- Safety profiling of emerging ocular medicines
Research in this area supports patients with diabetes‑related eye complications, a leading cause of vision loss.
Female Urogenital Diseases and Pregnancy Complications
The facility conducts trials on endometriosis and related reproductive health issues, testing interventions that aim to lessen disease severity and improve quality of life for women.
- Evaluation of hormonal modulators for endometriosis pain
- Imaging‑based endpoints to monitor disease progression
- Safety assessments of treatments during reproductive years
These studies address unmet needs in women’s health, offering potential new therapeutic options.
Hormonal Diseases
Research includes conditions linked to hormone regulation, such as vasomotor symptoms associated with breast cancer therapy, seeking effective relief without compromising cancer treatment.
- Trials of non‑hormonal agents for hot flash management
- Comparative studies of symptom‑control therapies
- Long‑term safety monitoring in hormone‑sensitive populations
The work supports patients undergoing endocrine treatments who experience disruptive symptoms.
Musculoskeletal Diseases
Investigations address knee osteoarthritis, focusing on therapies that aim to reduce pain and improve joint function.
- Immunotherapy approaches for inflammatory osteoarthritis
- Patient‑reported outcome measures for pain relief
- Physical function assessments in trial participants
This program strives to enhance mobility and daily living for individuals with degenerative joint disease.
Nervous System Diseases
Trials explore treatments for psychosis associated with Alzheimer’s disease and other neuropsychiatric conditions, aiming to improve cognition and behavioral outcomes.
- Evaluation of novel antipsychotic formulations
- Safety and tolerability studies in elderly cohorts
- Impact on caregiver burden and patient quality of life
The site’s neuroscience research contributes to better management of complex brain disorders.
Nutritional and Metabolic Diseases
The centre investigates metabolic disorders such as hypertriglyceridemia and diabetes, testing agents that aim to lower lipid levels and improve glycemic control.
- Lipid‑lowering therapies for severe triglyceride elevations
- Combination studies with glucose‑modulating drugs
- Cardiovascular risk reduction outcomes in metabolic patients
These efforts align with global initiatives to combat the rise of metabolic syndrome.
Respiratory Tract Diseases
Research includes acute upper‑respiratory conditions like rhinitis and rhinosinusitis, evaluating symptomatic treatments that do not require antibiotics.
- Nasal spray efficacy for non‑bacterial rhinitis
- Patient‑reported symptom relief scales
- Safety profiling in both adult and pediatric participants
The trials aim to provide effective, antibiotic‑sparing options for common respiratory complaints.
Virus Diseases
Ongoing studies address viral infections such as SARS‑CoV‑2 (COVID‑19), focusing on antiviral agents that reduce disease severity and prevent hospitalization.
- Oral antiviral efficacy in high‑risk outpatients
- Safety monitoring for viral therapeutics
- Outcomes related to viral clearance and symptom resolution
The work supports rapid development of treatments during pandemic conditions.
Mental Disorders
Trials target major depressive disorder and related mood conditions, evaluating novel compounds designed to alleviate depressive symptoms and improve daily functioning.
- Double‑blind studies of new antidepressant agents
- Genetic‑risk stratified enrollment strategies
- Assessment of treatment impact on quality of life
These investigations aim to expand therapeutic options for patients with treatment‑resistant depression.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 11 therapeutic areas and 15 of 70 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 66 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 17 by active trials.
lock +16 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC4trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Clinical Medical Research Sp. z o.o.
lock Showing 1 of 30 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of DT-101 in Adults with Major Depressive Disorder | Draig Therapeutics Limited | Phase II | Recruiting | Mar 2026 | — |
IMP list
lock Showing 1 of 70 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues | 3 | Unknown | 2024-11-04 | 2025-12-08 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.